↓ Skip to Main Content
Thasso
Thasso the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs

search: thasso

Log in

Main Navigation

  • english
    • english
    • français
    • deutsch
    • italiano
    • español
    • português
  • thasso
  • thasso post
  • thasso toolbox
    • theragenomics: useful links
    • theragenomics: biomarkers
    • theragenomics: companion tests
    • theragenomics: drug labels with annotated information
    • theragenomics: drugs and genes
    • theragenomics: the world of alleles
    • theragenomics: allele-related guideline information
    • drug interactions
    • drug information
    • drug adverse reactions
    • drugs: risk evaluation and mitigation strategies (REMS)
    • theragenomics: videos
  • thasso academy
    • health authorities
    • patient & consumer health
    • public domain
      • Swiss Academy of Medical Sciences
      • EUPATI The European Patients’ Academy on Therapeutic Innovation
    • companies
    • products
    • about
  • thasso community
    • thasso: simple chat
    • thasso: video chat
    • theragenomics: survey at thasso
      • survey participants
    • forum
      • patient groups / subgroups
      • group
      • lounge
      • events
      • gallery
  • thasso: about
    • vision
    • background
    • the apomediary patient
    • contact
    • disclaimers
    • policies
  • donations
    • thasso – thank you
    • Donation Confirmation

Tag: Exon 51

Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved

By Joseph Gut - thasso Posted on September 20, 2016 Posted in Genetic Background, In The Press, New Drug Approval, Personalized Medicine, Pharmacogenetics, Rare Diseases, Regulatory Approval, Targeted Therapy, Thasso Post, Theragenomic Medicine Tagged with American Food & Drug Administration (FDA), Duchenne Muscular Dystrophy (DMD), Dystrophin Gene, Eteplirsen (Exondys 51), Exon 51, Mutation, Targeted Therapy, Thasso Post, Theragenomic Medicine
Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved

September 19, 2016 – This post presents below a virtually unedited announcement by the American Food & Drug Administration (FDA) concerning Duchenne Muscular Dystrophy (DMD) therapy  option which gives much hope for at least some of the affected patients. However, be …

Eteplirsen (Exondys 51) for Duchenne Muscular Dystrophy (DMD) approved Read more »

Footer Menu

  • english
  • thasso
  • thasso post
  • thasso toolbox
  • thasso academy
  • thasso community
  • thasso: about
  • donations
Copyright © 2025 Thasso | Powered by Responsive Theme